Device/Diagnostics Quarterly Deal Statistics, Q4 2016

A look at the financing, M&A and alliance activity October–December 2016

Medtech companies raised $2.4 billion in the fourth quarter, the second-strongest of the year; Q4 device M&A deals totaled $9 billion in value, led by Allergan's $2.9 billion buy of Acelity's LifeCell division. Diagnostics financings finished out the year at $721 million, an increase over the previous quarter and 2016's second-highest quarter, but diagnostics M&A activity was the lowest of the year at $87 million, with only two completed acquisitions.

Quarterly Stats_1200x675

Device companies aggregated $2.4 billion in financing for the fourth quarter of 2016, representing an 18% decrease from Q3's $3 billion. Despite the decline, Q4 put up the second-strongest quarter of the year by value. In all, device fundraising totaled $8.9 billion in 2016, a huge 65% increase over 2015's $5.4 billion. (See Exhibit 1.) Much of the growth came from debt offerings, which at over $4 billion accounted for nearly half of 2016's financing aggregate. And among those were a couple of big outliers, including note sales by Nuvasive Inc. ($536 million [See Deal]) and Acelity LP Inc.'s Kinetic Concepts Inc. and KCI USA Inc. ($400 million [See Deal] and $1.8 billion, respectively. [See Deal])

Open Media

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.